Hereditary Spastic Paraplegia Overview

Peter Hedera

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021.

GeneReviews^® [Internet].

Show details

GeneReviews by Title

< Prev Next >

Hereditary Spastic Paraplegia Overview

Synonyms: Hereditary Spastic Paraparesis, Strumpell-Lorrain Syndrome

Peter Hedera, MD, PhD, FACMG.

Author Information

Initial Posting: August 15, 2000; Last Update: September 27, 2018.

Estimated reading time: 27 minutes

Summary

The purpose of this overview is to increase the awareness of clinicians regarding hereditary spastic paraplegia.

The following are the goals of this overview.

Goal 1.

Describe the clinical characteristics of hereditary spastic paraplegia and recommended treatment.

Goal 2.

Review the causes of hereditary spastic paraplegia.

Goal 3.

Consider the differential diagnosis of hereditary spastic paraplegia.

Goal 4.

Provide an evaluation strategy to identify the genetic cause of hereditary spastic paraplegia in a proband.

Goal 5.

Inform genetic counseling of family members of a proband with hereditary spastic paraplegia.

1. Clinical Characteristics and Recommended Treatment: Hereditary Spastic Paraplegia

The predominant signs and symptoms of hereditary spastic paraplegia (HSP) are lower-extremity weakness and spasticity.

Neurologic examination. Individuals with HSP demonstrate the following:

Bilateral lower-extremity spasticity (maximal in hamstrings, quadriceps, adductors, and gastrocnemius-soleus muscles) and weakness (maximal in the iliopsoas, hamstring, and tibialis anterior muscles). Spasticity and weakness are variable. Some individuals have spasticity and no demonstrable weakness, whereas others have spasticity and weakness in approximately the same proportions.
Lower-extremity hyperreflexia and extensor plantar responses
Often, mildly impaired vibration sensation in the distal lower extremities

Symptom onset

Early onset. When symptoms begin in very early childhood, they may be non-progressive and resemble spastic diplegic cerebral palsy.
Later onset. When symptoms begin in later childhood or after they usually progress slowly and steadily. After a number of years, it is not usual for individuals with progressively worsening gait to experience a "functional plateau" (i.e., the rate of further worsening of gait impairment is similar to that attributable to age).

Classification. HSP is classified clinically as "uncomplicated" (nonsyndromic) or "complicated" (syndromic).

Uncomplicated (or "pure") HSP is characterized by neurologic impairment limited to progressive lower-extremity spastic weakness, hypertonic urinary bladder disturbance, and mild diminution of lower-extremity vibration sensation [Harding 1983]. Individuals with uncomplicated HSP experience the following:
- Difficulty walking (may either be non-progressive or worsen insidiously)
- Often, the need for canes, walkers, or wheelchairs
- Possible urinary urgency and lower-extremity paresthesias
- Typically, normal strength and dexterity of the upper extremities
- No involvement of speech, chewing, or swallowing
Though symptoms may be disabling, life span is not shortened.
Complicated HSP is characterized by the impairments present in uncomplicated HSP plus other system involvement or other neurologic findings including any of the following:*
- Ataxia
- Seizures
- Intellectual disability
- Dementia
- Muscle atrophy
- Extrapyramidal disturbance
- Peripheral neuropathy
*In the absence of other causes for these additional features

Treatment of Manifestations

At present, there is no specific treatment to prevent or reverse nerve degeneration in HSP. Treatments are directed at reducing symptoms and improving balance, strength, and agility. Individuals should be evaluated periodically (annually or as needed) by a neurologist and physiatrist to assess progression and develop treatment strategies to maximize walking ability and reduce symptoms.

Current recommendations:

Daily regimen of physical therapy directed toward improving cardiovascular fitness, maintaining and improving muscle strength and gait, and reducing spasticity
Occupational therapy, assistive walking devices, and ankle-foot orthotics as needed
Drugs to reduce muscle spasticity (e.g., Lioresal^® [oral or intrathecal], tizanidine, dantrolene, botulinum A and B toxin injections [Botox^®, Dysport, Xeomin, or Myoblock]) and urinary urgency (e.g., oxybutynin, solifenacin, mirabegron, or intrabladder injections with Botox^®)

2. Causes of Hereditary Spastic Paraplegia

Genetic types of hereditary spastic paraplegia (HSP). To date, more than 80 genetic types of HSP have been defined by genetic linkage analysis and identification of HSP-related gene variants. In the past, genetic loci for HSP were designated SPG (for "spastic paraplegia") and numbered in order of their discovery. With the identification of the causative genes at those loci, reference by clinicians and clinical labs to a specific genetic type of HSP has moved to the name of the gene rather than the locus designation. Autosomal dominant, autosomal recessive, X-linked, and maternally inherited (mitochondrial) forms of HSP have been identified.

Autosomal dominant HSP is the most common type of HSP, found in 75%-80% of affected individuals.

SPG4, caused by a pathogenic variant in SPAST, is the most common type, accounting for approximately 40% of all autosomal dominant HSP.
SPG3A, caused by a pathogenic variant in ATL1, is the second most common type of autosomal dominant HSP, accounting for approximately 10%-15% of all autosomal dominant HSP. SPG3A is the main cause of autosomal dominant HSP with early onset (occurs in >75% of individuals in this category).
SPG31, caused by a pathogenic variant in REEP1, is relatively common, accounting for about 5% of all autosomal dominant HSP.
Other types of autosomal dominant HSP with a predominantly adult onset are relatively rare and most of them account for 1% or less of all autosomal dominant HSP.

Autosomal recessive HSP is very heterogeneous, with an ever-growing list of newly identified genes. Many new causes of autosomal recessive HSP are very rare and may be limited to a single family or even a single individual. The frequency is increased in populations with a higher degree of consanguinity. AR HSP is found in an estimated 25%-30% of all individuals with HSP.

Most common types of autosomal recessive HSP are encountered in the general population:

SPG5A, caused by pathogenic variants in CYP7B1, accounts for 7.3% of all autosomal recessive HSP and 3% of apparently sporadic pure spastic paraplegia.
SPG7, caused by pathogenic variants in SPG7, may account for approximately 5% of all autosomal recessive HSP.
SPG11, caused by pathogenic variants in SPG11, accounts for 3%-5% of all autosomal recessive HSP but is found in 75% of individuals with all types of HSP who have radiologic signs of thin or absent corpus callosum.

X-linked HSP and mitochondrial HSP are the rarest genetic forms of HSP, accounting for fewer than 1%-2% of all individuals affected with HSP.

Other. Several types of HSP (e.g., those associated with pathogenic variants in ATL1 [Khan et al 2014], SPG7 [McDermott et al 2001], and ALDH18A1 [Coutelier et al 2015]) may be inherited as either autosomal recessive or autosomal dominant disorders.

Table 1.

Hereditary Spastic Paraplegia: Genes and Distinguishing Clinical Features – Autosomal Dominant Inheritance

Gene ¹	HSP Designation	Type of HSP	Onset	Distinguishing Clinical Features	Other	References
Gene ¹	HSP Designation	Type of HSP	Onset	Distinguishing Clinical Features	Other	GeneReview or OMIM Entry	Citation
ADAR	Not assigned	Uncomplicated	Early childhood	Abnormal pattern of interferon expression determined by reverse transcription PCR assay	Reported in a single Hispanic individual		Crow et al [2014]
ALDH18A1	SPG9A	Complicated	Adolescence to adulthood (1 subject w/infantile onset)	Cataracts Gastroesophageal reflux Motor neuronopathy Variably present: Dysarthria Ataxia Cognitive impairment	Rare Allelic w/AR HSP (SPG9B)	OMIM 601162	Coutelier et al [2015]
ATAD3A	Not assigned	Complicated	Early onset	Amyotrophy Hyperkinetic movements May be confused w/hyperkinetic cerebral palsy	Rare		Cooper et al [2017]
ATL1	SPG3A	Uncomplicated	Infantile to childhood (rarely adult onset)	Progression may be minimal w/static course. May present as spastic diplegic cerebral palsy Complicated phenotype w/peripheral neuropathy or autonomic failure reported	80% of early-onset AD HSP 10%-15% of all AD HSP	Spastic Paraplegia 3A	Zhao et al [2001], Namekawa et al [2006], Rainier et al [2006], Ivanova et al [2007]
BICD2	Not assigned	Complicated	Childhood or adult	Infantile onset associated w/SMA w/variable upper motor signs & contractures Adult onset associated w/mild amyotrophy	Rare		Oates et al [2013]
BSCL2 ²	SPG17	Complicated	Adulthood	Distal amyotrophy affecting hands & feet Motor neuropathy Can be indistinguishable from ALS	Rare	BSCL2-Related Neurologic Disorders/ Seipinopathy	Windpassinger et al [2004], Musacchio et al [2017]
CPT1C	SPG73	Uncomplicated	Early adulthood	Foot deformity may be present.	Single family	OMIM 616282	Rinaldi et al [2015]
DNM2 ³	Not assigned	Complicated	Before age 20 years	Axonal polyneuropathy may be present. Mild distal amyotrophy in feet	Single family		Sambuughin et al [2015]
ERLIN2	SPG18 ⁴	Uncomplicated	Juvenile to adulthood	None	Single family Most pathogenic variants assoc w/AR HSP (see Table 2)		Rydning et al [2018]
HSPD1	SPG13	Uncomplicated	Adulthood	Mild distal amyotrophy	Rare	OMIM 605280	Hansen et al [2002]
KIF5A ⁴	SPG10	Complicated	Juvenile or adulthood	Polyneuropathy Pes cavus	1%-2% of all AD HSP 5%-8% of all complicated AD HSP	OMIM 604187	Reid et al [2002], Blair et al [2006], Liu et al [2014]
NIPA1	SPG6	Uncomplicated	Adulthood (infantile onset rare)	Severe weakness & spasticity Rapidly progressive Rarely, complicated by epilepsy or variable peripheral neuropathy	Rare (~1% of AD HSP)	OMIM 600363	Rainier et al [2003], Du et al [2011], Svenstrup et al [2011], Hedera [2013]
ATP2B4 (PMCA4)	Not assigned	Uncomplicated	Adulthood	None	Single family		Li et al [2014]
REEP1	SPG31	Uncomplicated	Variable from 2nd to 7th decades	Mild amyotrophy variably present.	Common, 4%-6% of all AD HSP	OMIM 610250	Züchner et al [2006], Hewamadduma et al [2009]
REEP2	SPG72	Uncomplicated	Very early, average age 4 years	Musculoskeletal problems Mild postural tremor	Rare Inheritance can be dominant or recessive	OMIM 615625	Esteves et al [2014]
RTN2	SPG12	Uncomplicated	Before age 20 years	None	5% of early-onset AD HSP but overall rare	OMIM 604805	Montenegro et al [2012]
SLC33A1	SPG42	Uncomplicated	Early adulthood	Slowly progressive Mild pes cavus	Single family known	OMIM 612539	Lin et al [2008]
SPAST	SPG4	Uncomplicated	Variable from infancy to 7th decade	Cognitive decline & dementia common Distal amyotrophy variably present Complicated phenotype w/ataxia variably present	40% of AD HSP	Spastic Paraplegia 4	Hazan et al [1999], Fonknechten et al [2000], Nielsen et al [2004], Murphy et al [2009]
SPG7	SPG7	Uncomplicated or complicated	Juvenile or adulthood	Dysarthria Ataxia Optic atrophy Supranuclear palsy Mitochondrial abnormalities on skeletal muscle biopsy	AD inheritance suggested for some pathogenic variants, but overall this is rare	Spastic Paraplegia 7	McDermott et al [2001]
WASHC5	SPG8	Uncomplicated	Adulthood (rare infantile onset reported)	Severe motor deficit in some individuals	Rare (~1% of AD HSP)	Spastic Paraplegia 8	Hedera et al [1999], Valdmanis et al [2007]
TUBB4A ⁵	Not assigned	Complicated	Juvenile	Cerebellar ataxia MRI evidence of hypomyelination	Rare		Kancheva et al [2015]
ZFYVE27	SPG33	Uncomplicated	Adulthood	Mild pes cavus	Single family known	OMIM 610244	Mannan et al [2006]

: AD = autosomal dominant; AR = autosomal recessive; ALS = amyotrophic lateral sclerosis; CMT = Charcot-Marie-Tooth neuropathy; DI-CMT = dominant intermediate Charcot-Marie-Tooth neuropathy; HMN = hereditary motor neuropathy; HSP = hereditary spastic paraplegia; SMA = spinal muscular atrophy
1.: Genes are listed alphabetically.
2.: Allelic w/distal hereditary motor neuropathy type V (dHMN-V) and variants of Charcot-Marie-Tooth disease type 2
3.: Allelic with CMT2M; DI-CMTB, centronuclear myopathy; & lethal congenital contractures syndrome type 5
4.: Allelic to Charcot-Marie-Tooth disease axonal CMT2A and ALS25 (susceptibility to ALS)
5.: Allelic with hypomyelinating leukodystrophy type 6 and autosomal dominant dystonia type 4

Table 2.

Hereditary Spastic Paraplegia: Genes and Distinguishing Clinical Features – Autosomal Recessive Inheritance

Gene ¹	HSP Designation	Type of HSP	Onset	Distinguishing Clinical Features	Other	References
Gene ¹	HSP Designation	Type of HSP	Onset	Distinguishing Clinical Features	Other	GeneReview or OMIM Entry	Citation
SPG21 (ACP33)	SPG21	Complicated	Childhood	Ataxia Adult-onset dementia & parkinsonism Polyneuropathy Akinetic mutism seen in advanced cases	Rare, first described in Old Order Amish population (later identified in various ethnic groups) Also known as Mast syndrome	OMIM 248900	Cross & McKusick [1967a], Simpson et al [2003], Ishiura et al [2014]
ALDH18A1	SPG9B	Complicated	Adolescence to adulthood (one subject w/infantile onset)	Cataracts Gastroesophageal reflux Motor neuronopathy Variably present: Dysarthria Ataxia Cognitive impairment	Rare Allelic w/AD HSP (SPG9A)	OMIM 616586	Coutelier et al [2015]
ALDH3A2	Not assigned	Complicated	Childhood	Congenital ichthyosis Macular dystrophy Leukodystrophy Seizures in ~40% of patients	Rare Most common in people of Swedish ancestry Known as Sjögren-Larsson syndrome		Rizzo et al [1999], Gordon [2007]
AMPD2 ²	SPG63	Complicated	Infancy	Short stature Thin corpus callosum White matter changes	Rare	OMIM 615686	Novarino et al [2014], Kortüm et al [2018]
AP4B1	SPG47	Complicated	Infancy	Severe ID Facial dysmorphism Seizures Stereotypic laughter w/tongue protrusion	Rare	OMIM 614066	Abou Jamra et al [2011], Bauer et al [2012]
AP4E1	SPG51	Complicated	Infancy	Severe ID Facial dysmorphism Seizures Stereotypic laughter w/tongue protrusion	Rare	OMIM 613744	Abou Jamra et al [2011], Moreno-De-Luca et al [2011]
AP4M1	SPG50	Complicated	Infancy	Severe ID Facial dysmorphism Seizures Stereotypic laughter w/tongue protrusion	Rare	OMIM 612936	Verkerk et al [2009]
AP4S1	SPG52	Complicated	Infancy	Severe ID Facial dysmorphism Seizures Stereotypic laughter w/tongue protrusion	Rare	OMIM 614067	Abou Jamra et al [2011], Hardies et al [2015]
AP5Z1	SPG48	Uncomplicated	Typically adulthood; rarely infancy	Urinary incontinence Parkinsonism Dystonia Thin corpus callosum Leukodystrophy Severe DD in infantile onset	Single family	OMIM 613647	Słabicki et al [2010], Pensato et al [2014]
ATL1	SPG3A	Uncomplicated	Infantile to childhood (rarely adult onset)	Progression may be minimal w/static course May present as spastic diplegic cerebral palsy Complicated phenotype w/peripheral neuropathy or autonomic failure reported	AR inheritance is very rare.	Spastic Paraplegia 3A	Khan et al [2014]
B4GALNT1	SPG26	Complicated	Juvenile	Amyotrophy Dysarthria Ataxia DD Dystonia	Rare	OMIM 609195	Boukhris et al [2013], Harlalka et al [2013]
BICD2	Not assigned	Complicated	Childhood	Amyotrophy Contractures	Rare		Oates et al [2013]
MTRFR (C12orf65)	SPG55	Complicated	Childhood	DD Visual loss Polyneuropathy Arthrogryposis Signs of mitochondrial encephalomyopathy, some classified as Leigh's syndrome	Rare	OMIM 615035	Shimazaki et al [2012]
C19orf12	SPG43	Complicated	Childhood	Amyotrophy Dysarthria Multiple contractures Neurodegeneration w/brain iron accumulation in some	Rare	OMIM 615043	Landouré et al [2013], Schubert et al [2016]
CYP2U1	SPG56	Complicated	Infancy	Severe DD Dystonia Polyneuropathy Calcification of basal ganglia	Rare	OMIM 615030	Tesson et al [2012]
CYP7B1	SPG5A	Uncomplicated or complicated	Juvenile to early adulthood	Ataxia Polyneuropathy Extrapyramidal signs MRI signs of leukodystrophy	SPG5A was diagnosed in 9 of 172 families w/histories consistent w/AR inheritance of HSP. ³	OMIM 270800	Tsaousidou et al [2008], Goizet et al [2009]
DDHD1	SPG28	Uncomplicated	Childhood	Scoliosis	Rare	OMIM 609340	Tesson et al [2012]
DDHD2	SPG54	Complicated	Infancy	Severe DD Optic atrophy Thin corpus callosum Leukodystrophy	Rare	OMIM 615033	Schuurs-Hoeijmakers et al [2012]
ENTPD1	SPG64	Complicated	Infancy	Mild cognitive disability Behavioral disturbances White matter changes	Rare	OMIM 615683	Novarino et al [2014]
ERLIN1	SPG62	Complicated	Childhood	Amyotrophy Ataxia Phenotype consistent w/juvenile onset of ALS reported	Rare	OMIM 615681	Novarino et al [2014], Tunca et al [2018]
ERLIN2	SPG18	Complicated (rarely pure AR HSP reported)	Childhood	DD Seizures Contractures Juvenile primary lateral sclerosis phenotype reported Allelic w/AD pure HSP	Rare	OMIM 611225	Alazami et al [2011], Yıldırım et al [2011], Al-Saif et al [2012]
FA2H ⁴	SPG35	Complicated	Childhood	Seizures Dystonia Parkinsonism w/iron accumulation in basal ganglia	Rare	OMIM 612319	Edvardson et al [2008], Dick et al [2010], Pensato et al [2014]
GAD1	Not assigned	Complicated	Childhood	Moderate to severe ID Single reported family was described as having AR cerebral palsy	Rare (single family reported)		Lynex et al [2004]
GBA2	SPG46	Complicated	Childhood	DD Ataxia Hearing loss Polyneuropathy	Rare	OMIM 614409	Hammer et al [2013], Coarelli et al [2018]
GJC2 ⁵	SPG44	Complicated	Childhood	Febrile seizures Deafness Episodic spasms Variable degree of leukodystrophy	Rare	OMIM 613206	Uhlenberg et al [2004], Orthmann-Murphy et al [2009]
GRID2 ⁶	Not assigned	Complicated	Childhood	Amyotrophy Ataxia	Rare		Utine et al [2013], Maier et al [2014]
IBA57 ⁷	SPG74	Complicated	Childhood	Optic atrophy Peripheral neuropathy	Rare	OMIM 616451	Lossos et al [2015], Torraco et al [2017]
KIF1A ⁸	SPG30	Complicated	Childhood	Spastic ataxia Polyneuropathy	Rare	OMIM 610357	Hamdan et al [2011], Rivière et al [2011], Klebe et al [2012]
KIF1C	SPG58	Complicated	Childhood	Spastic ataxia Dystonia	Rare		Caballero Oteyza et al [2014], Dor et al [2014]
KLC2	Not assigned	Complicated	Childhood	Optic atrophy Neuropathy Contractures in later stages Cognition remains intact	Rare Also known as spastic paraplegia optic atrophy, & neuropathy (SPOAN)	OMIM 609541	Melo et al [2015]
KLC4	Not assigned	Complicated	Childhood	Ataxia Multiple contractures Variable degree of leukodystrophy	Rare		Bayrakli et al [2015]
MARS1 ⁹	SPG70	Complicated	Infancy	Nephrotic syndrome, polyneuropathy Mild ID Late onset of CMT2 (axonal) type also reported	Rare		Gonzalez et al [2013], Novarino et al [2014]
NT5C2	SPG45	Complicated	Childhood	Optic atrophy Nystagmus Strabismus ID Hypoplastic corpus callosum	Rare	OMIM 613162	Novarino et al [2014], Elsaid et al [2017]
PGAP1 ¹⁰	SPG67	Complicated	Infancy	Severe DD Tremor Agenesis of corpus callosum Hypomyelination	Rare		Murakami et al [2014], Novarino et al [2014]
PNPLA6 ¹¹	SPG39	Complicated	Childhood	Amyotrophy Endocrine abnormalities w/short stature or hypogonadotropic hypogonadism Chorioretinal dystrophy	Rare	PNPLA6-Related Disorders	Rainier et al [2008], Synofzik et al [2014], Hufnagel et al [2015]
REEP2	SPG72	Uncomplicated	Early childhood	Musculoskeletal problems Mild postural tremor	Rare Inheritance can be dominant or recessive.	OMIM 615625	Esteves et al [2014]
SPART	SPG20	Complicated	Juvenile	Distal amyotrophy Short stature Kyphoscoliosis Multiple limb contractures	Rare Mostly seen among Old Order Amish	Troyer Syndrome	Cross & McKusick, [1967b], Patel et al [2002]
SPG7	SPG7	Uncomplicated or complicated	Juvenile or adulthood	Dysarthria Ataxia Optic atrophy Supranuclear palsy Mitochondrial abnormalities on skeletal muscle biopsy	5%-12% of AR HSP AD inheritance suggested for some pathogenic variants; this remains controversial	Spastic Paraplegia 7	Casari et al [1998], McDermott et al [2001], Arnoldi et al [2008], Brugman et al [2008]
SPG11	SPG11	Complicated	Childhood or early adulthood	DD Optic atrophy Ataxia Pseudobulbar signs Polyneuropathy Levodopa-responsive parkinsonism Hypoplastic or absent corpus callosum	5% of AR HSP 75% of HSP w/DD & hypoplasia of corpus callosum	Spastic Paraplegia 11	Stevanin et al [2007], Paisan-Ruiz et al [2008], Riverol et al [2009], Guidubaldi et al [2011]
TECPR2	SPG49	Complicated	Childhood	Central apnea Severe DD Microcephaly Dysmorphic features	Rare	OMIM 615031	Oz-Levi et al [2012]
TFG	SPG57	Complicated	Childhood	Optic atrophy Severe polyneuropathy	Rare	OMIM 615658	Beetz et al [2013]
USP8	SPG59	Uncomplicated	Childhood	None	Rare		Novarino et al [2014]
WDR48	SPG60	Complicated	Infancy	Polyneuropathy DD	Rare		Novarino et al [2014]
ZFYVE26	SPG15	Complicated	Childhood or early adulthood	DD Optic atrophy Ataxia Central retinal degeneration Polyneuropathy	1%-2% of AR HSP	OMIM 270700	Hanein et al [2008], Pensato et al [2014]

: AD = autosomal dominant; AR = autosomal recessive; ALS = amyotrophic lateral sclerosis; DD = developmental delay; HSP = hereditary spastic paraplegia; ID = intellectual disability
1.: Genes are listed alphabetically.
2.: Allelic with pontocerebellar hypoplasia type 9
3.: Goizet et al [2009]
4.: Allelic with fatty acid hydroxylase-associated neurodegeneration and leukodystrophy
5.: Allelic with Pelizaeus-Merzbacher-like disease 1 and hereditary lymphedema type IC
6.: Allelic with autosomal recessive spinocerebellar ataxia 18 (see Hereditary Ataxia Overview)
7.: Allelic with multiple mitochondrial dysfunctions syndrome 3
8.: Allelic with hereditary sensory and autonomic neuropathy type 2C and AD intellectual disability type 9
9.: Allelic with Charcot-Marie-Tooth neuropathy type 2U
10.: Allelic with autosomal recessive intellectual disability type 42
11.: Allelic with Boucher-Neuhauser syndrome, Gordon-Holmes syndrome, Oliver-McFarlane syndrome, and Laurence-Moon syndrome

Table 3.

Hereditary Spastic Paraplegia: Genes and Distinguishing Clinical Features – X-Linked Inheritance

Gene ¹	HSP Designation	Type of HSP	Onset	Distinguishing Clinical Features	Other	References
Gene ¹	HSP Designation	Type of HSP	Onset	Distinguishing Clinical Features	Other	GeneReview or OMIM Entry	Citation
L1CAM ²	SPG1	Complicated	Infancy	ID Adducted thumbs Corpus callosum hypoplasia Aphasia Obstructive hydrocephalus	Rare	L1 Syndrome	Jouet et al [1994], Schrander-Stumpel et al [1995], Yamasaki et al [1995], Finckh et al [2000]
PLP1 ³	SPG2	Complicated	Early-childhood to juvenile onset (in manifesting female heterozygotes: onset in 4th-7th decade)	Pure HSP phenotype present in early stages; later, other signs emerge Nystagmus Optic atrophy Dysarthria ID Variable degree of leukodystrophy on MRI	Rare In heterozygous females: variable phenotype w/relatively late onset & mild clinical manifestations	PLP1-Related Disorders	Saugier-Veber et al [1994], Cambi et al [1996], Hodes et al [1999], Sivakumar et al [1999]
SLC16A2	SPG22	Complicated	Early childhood	Severe ID Infantile hypotonia Progressive spasticity Ataxia Dystonia ↑ T3 & normal to mildly ↑ TSH ↓ T4 hypomyelination on neuroimaging	Rare SPG22 is a proposed designation. ⁴ Also referred to as Allan-Herndon-Dudley syndrome ⁵	Allan-Herndon-Dudley Syndrome	Dumitrescu et al [2004], Boccone et al [2010]

: AD = autosomal dominant; AR = autosomal recessive; DD = developmental delay; HSP = hereditary spastic paraplegia; ID = intellectual disability
1.: Genes are listed alphabetically.
2.: Allelic with X-linked hydrocephalus with stenosis of the aqueduct of Sylvius; MASA syndrome (mental retardation, aphasia [delayed speech], spastic paraplegia [shuffling gait], adducted thumbs); and X-linked complicated corpus callosum agenesis accounting for 5%-10% of all non-syndromic congenital obstructive hydrocephalus
3.: Allelic with Pelizaeus-Merzbacher disease
4.: OMIM 300523
5.: Because of the overlap between the clinical phenotype in individuals with SLC16A2 abnormalities and in those with a previously described syndrome, Allan-Herndon-Dudley syndrome (AHDS), Schwartz et al [2005] analyzed SLC16A2 in six families with AHDS. SLC16A2 pathogenic variants were identified in all six; therefore, AHDS is now synonymous with MCT8-specific thyroid hormone cell-membrane transporter deficiency due to pathogenic variants in SLC16A2 (see Allan-Herndon-Dudley Syndrome).

Table 4.

Hereditary Spastic Paraplegia: Gene and Distinguishing Clinical Features – Maternal (Mitochondrial) Inheritance

Gene	HSP Designation	Type of HSP	Onset	Distinguishing Clinical Features
MT-ATP6	Not assigned	Complicated	Adult	Cardiomyopathy, diabetes mellitus, sensory polyneuropathy

: Verny et al [2011]

3. Differential Diagnosis of Hereditary Spastic Paraplegia

The differential diagnosis includes the following:

Structural abnormalities involving the brain or spinal cord (e.g., tethered cord syndrome and spinal cord compression)
Vascular abnormalities including arteriovenous abnormalities or fibrocartilaginous embolism
Demyelinating disorders including primary progressive multiple sclerosis or Devi's disease (neuromyelitis optica)
Paraneoplastic myelopathies including those associated with anti-GAD65 antibodies
Other motor neuron disorders such as slowly progressive amyotrophic lateral sclerosis (ALS) or primary lateral sclerosis (PLS)
Leukodystrophies such as steadily progressive multiple sclerosis, B₁₂ deficiency, Krabbe disease, metachromatic leukodystrophy, and adrenomyeloneuropathy
Spinocerebellar ataxias (SCAs) including Machado-Joseph disease (SCA 3), Friedreich ataxia, spastic ataxia of Charlevoix-Saguenay, or other spastic ataxias. See Hereditary Ataxias.
Diplegic form of cerebral palsy (CP) with corresponding MR imaging abnormalities. However, several individuals with presumed CP have had pathogenic variants in genes associated with HSP identified on molecular genetic testing associated with either an autosomal dominant or autosomal recessive inheritance [Rainier et al 2006, Hedera 2013].
Infection including human immunodeficiency virus (HIV/AIDs), tropical spastic paraplegia (also known as human T-cell leukemia virus 1 [HTLV1] -associated myelopathy), and neurosyphilis
Metabolic disorders (reviewed in Hedera [2016]) including homocysteine remethylation defects (due to methylene tetrahydrofolate reductase [MTHFR] deficiency), cobalamin C disease, urea cycle defects, biotinidase deficiency, phenylketonuria, glycine encephalopathy, cerebral folate deficiency, homocarnosinosis, cerebrotendinous xanthomatosis, adult polyglucosan body disease, and nucleoside phosphorylase deficiency
Nutritional disorders (reviewed in Hedera [2016]) including copper deficiency, vitamin B₁₂ and E deficiencies
Early-onset dementias including frontotemporal dementia-ALS (see Amyotrophic Lateral Sclerosis Overview) and familial Alzheimer disease caused by pathogenic variants in PSEN1 (encoding presenilin-1), PSEN2 (encoding presenilin-2), or APP (encoding amyloid precursor protein) (see Alzheimer Disease)
Dopa-responsive dystonia. It is important to consider dopa-responsive dystonia in all individuals – particularly children – with progressive gait disturbance. See GTP Cyclohydrolase 1-Deficient Dopa-Responsive Dystonia, Tyrosine Hydroxylase Deficiency.

4. Evaluation Strategies to Identify the Genetic Cause of Hereditary Spastic Paraplegia in a Proband

Establishing a specific genetic cause of hereditary spastic paraplegia (HSP):

Can aid in discussions of prognosis (which are beyond the scope of this GeneReview) and genetic counseling;
Usually involves a medical history, physical examination, laboratory testing, family history, and genomic/genetic testing.

Medical history and physical examination is directed at identifying neurologic features associated with HSP as well as any additional features that could indicate the presence of a complicated HSP (see Clinical Characteristics and Tables 1, 2, 3, and 4).

Family history includes a three-generation family history with attention to other relatives with possible HSP. Documentation of relevant findings in family members can be accomplished either through direct examination of those individuals or through review of their medical records including neuroimaging, neuropathology, neurologic examination, and results of molecular genetic testing. Autosomal dominant, autosomal recessive, and X-linked or maternal (mitochondrial) inheritance patterns have all been reported with HSP.

Exclusion of other disorders. See Differential Diagnosis.

Molecular genetic testing approaches can include a combination of gene-targeted testing (single-gene testing or multigene panel) and comprehensive genomic testing (exome sequencing, exome array). Gene-targeted testing requires the clinician to hypothesize which gene(s) are likely involved, whereas genomic testing does not.

Concurrent or serial single-gene testing can be considered if clinical findings and/or family history indicate that involvement of a particular gene or small subset of genes is most likely (see Tables 1, 2, 3, and 4).
A multigene panel that includes some or all of the genes listed in Table 1 is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.
For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.
Comprehensive genomic testing (which does not require the clinician to determine which gene[s] are likely involved) may be considered. Exome sequencing is most commonly used; genome sequencing is also possible. Exome array (when clinically available) may be considered if exome sequencing is not diagnostic.
For an introduction to comprehensive genomic testing click here. More detailed information for clinicians ordering genomic testing can be found here.

5. Genetic Counseling

Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may face or to substitute for consultation with a genetics professional. —ED.

Mode of Inheritance

Hereditary spastic paraplegia (HSP) can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner or by maternal (mitochondrial) inheritance, depending on the genetic subtype in a family.

Several types of HSP (e.g., those associated with pathogenic variants in ATL1, SPG7, ALDH18A1, and possibly SPG11) may be inherited either as autosomal recessive or autosomal dominant disorders (see Causes of Hereditary Spastic Paraplegia).

Risk to Family Members

Autosomal Dominant HSP

Parents of a proband

Most individuals diagnosed as having an autosomal dominant HSP have an affected parent.
Occasionally, a proband with HSP may have the disorder as the result of a de novo pathogenic variant. The frequency of de novo variants causing autosomal dominant HSP is unknown.
Recommendations for the evaluation of parents of a proband with an apparent de novo pathogenic variant include molecular genetic testing of both parents for the pathogenic variant identified in the proband.
If the pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, possible explanations include a de novo pathogenic variant in the proband or germline mosaicism in a parent. Parental germline mosaicism has been reported in SPAST-related HSP (SPG4) [Aulitzky et al 2014]. The incidence of parental germline mosaicism is probably very low, but no conclusive epidemiologic data are available.

Sibs of a proband

The risk to the sibs of the proband depends on the genetic status of the proband's parents: if one of the proband's parents has a pathogenic variant, the risk to the sibs of inheriting the pathogenic variant is 50%.
The age of onset and degree of disability are highly variable among members of the same family, in different families with the same pathogenic variant, or between genetic types of HSP.
If the HSP-related pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, the risk to sibs is slightly greater than that of the general population (though still <1%) because of the theoretic possibility of parental germline mosaicism.

Offspring of a proband. Each child of an individual with autosomal dominant HSP is at a 50% risk of inheriting the HSP-related pathogenic variant.

Other family members. The risk to other family members depends on the status of the proband's parents: if a parent is affected, his or her family members may be at risk.

Autosomal Recessive HSP

Parents of a proband

The parents of an affected individual are obligate heterozygotes (i.e., carriers of one HSP-related pathogenic variant).
Heterozygotes (carriers) are typically asymptomatic. The only known exception to this rule is SPG7, where an apparently dominant inheritance was suggested for otherwise autosomal recessive HSP [McDermott et al 2001].

Sibs of a proband

At conception, each sib has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
Heterozygotes are typically asymptomatic if the pattern of inheritance is consistent with autosomal recessive mode and affected individuals harbor biallelic pathogenic variants.

Offspring of a proband. The offspring of an individual with autosomal recessive HSP are obligate heterozygotes (carriers) for an HSP-related pathogenic variant.

Other family members. Each sib of the proband's parents is at a 50% risk of being a carrier of an HSP-related pathogenic variant.

X-Linked HSP

Parents of a male proband

The father of an affected male will not have the disorder nor will he be hemizygous for the HSP-related pathogenic variant; therefore, he does not require further evaluation/testing.
In a family with more than one individual with X-linked HSP, the mother of an affected male is an obligate carrier of the HSP-related pathogenic variant. If a woman has more than one affected child and if the HSP-related pathogenic variant cannot be detected in her leukocyte DNA, she most likely has germline mosaicism (maternal germline and somatic mosaicism in L1CAM-related HSP [SPG1] has been reported [Du et al 1998, Vits et al 1998]).
If a male is the only affected family member (i.e., a simplex case), the mother may be a heterozygote or the affected male may have a de novo HSP-related pathogenic variant, in which case the mother is not a heterozygote.

Parents of a female proband

A female proband may have inherited the HSP-related pathogenic variant from either her mother or her father, or the pathogenic variant may be de novo.
Detailed evaluation of the parents and review of the extended family history may help distinguish probands with a de novo pathogenic variant from those with an inherited pathogenic variant. Molecular genetic testing of the mother (and possibly the father, or subsequently the father) can determine if the pathogenic variant was inherited.

Sibs of a male proband

The risk to sibs depends on the genetic status of the mother.
- If the mother of the proband with X-linked HSP has an HSP-related pathogenic variant, the chance of transmitting it in each pregnancy is 50%. Males who inherit the variant will be affected; females who inherit the variant will be heterozygotes and may have a range of clinical manifestations (see Table 3).
- If the proband represents a simplex case (i.e., a single occurrence in a family) and if the HSP-related pathogenic variant cannot be detected in the leukocyte DNA of the mother, the risk to sibs is slightly greater than that of the general population (though still <1%) because of the theoretic possibility of maternal germline mosaicism.
The age of onset, penetrance, and degree of disability are not predictable in members of the same family, in different families with the same pathogenic variant, or between genetic types of HSP.

Sibs of a female proband

The risk to sibs depends on the genetic status of the parents.
- If the mother of the proband has an HSP-related pathogenic variant, the chance of transmitting it in each pregnancy is 50%. Males who inherit the variant will be affected; females who inherit the variant will be heterozygotes and may have a range of clinical manifestations (see Table 3).
- If the father of the proband has an HSP-related pathogenic variant, he will transmit it to all of his daughters and none of his sons.
If the proband represents a simplex case (i.e., a single occurrence in a family) and if the HSP-related pathogenic variant cannot be detected in the leukocyte DNA of either parent, the risk to sibs is slightly greater than that of the general population (though still <1%) because of the possibility of parental germline mosaicism.
The age of onset, penetrance, and degree of disability are not predictable in members of the same family, in different families with the same pathogenic variant, or between genetic types of HSP.

Offspring of a male proband. Affected males transmit the HSP-related pathogenic variant to:

All of their daughters, who will be heterozygotes and may have a range of clinical manifestations (see Table 3);
None of their sons.

Offspring of a female proband. Women with an HSP-related pathogenic variant have a 50% chance of transmitting the pathogenic variant to each child:

Males who inherit the pathogenic variant will be affected.
Females who inherit the variant will be heterozygotes and may have a range of clinical manifestations (see Table 3). This is best documented for SPG2, where female heterozygotes may show a mild paraparesis with late onset of the disease [Sivakumar et al 1999].

Other family members. The risk to other family members depends on the status of the proband's parents: if a parent has the HSP-related pathogenic variant, his or her family members may be at risk.

Heterozygote (carrier) detection. Molecular genetic testing of at-risk female relatives to determine their genetic status is most informative if the pathogenic variant has been identified in the proband.

Note:

(1) Females who are heterozygous for X-linked HSP may have a range of clinical manifestations (see Table 3).

(2) Identification of female heterozygotes requires either (a) prior identification of the HSP-related pathogenic variant in the family or, (b) if an affected male is not available for testing, molecular genetic testing first by sequence analysis, and if no pathogenic variant is identified, by gene-targeted deletion/duplication analysis.

Maternal (Mitochondrial) Inheritance

Parents of a proband

The father of a proband is not at risk of having the MT-ATP6 pathogenic variant.
The mother of a proband (usually) has the MT-ATP6 pathogenic variant and may or may not have symptoms.
Alternatively, the proband may have a de novo (somatic) mitochondrial pathogenic variant.

Sibs of a proband

The risk to the sibs depends on the genetic status of the mother.
If the mother has the MT-ATP6 pathogenic variant, all sibs of a proband will inherit the MT-ATP6 pathogenic variant and may or may not have symptoms.

Offspring of a proband

All offspring of females with a mtDNA pathogenic variant will inherit the pathogenic variant.
Offspring of males with a mtDNA pathogenic variant are not at risk of inheriting the pathogenic variant.

Other family members. The risk to other family members depends on the genetic status of the proband's mother. If the mother has an MT-ATP6 pathogenic variant, her sibs and mother are also at risk.

Related Genetic Counseling Issues

Caution must be exercised when counseling an individual who has all the signs and symptoms of HSP but no similarly affected relatives. Such individuals may be diagnosed as having primary lateral sclerosis (PLS). While such individuals with no known family history of HSP may have autosomal recessive HSP (and thus low risk of transmitting the disorder to offspring), it is also possible that they have X-linked HSP, autosomal dominant HSP with reduced penetrance, a de novo pathogenic variant, a mtDNA pathogenic variant, mistaken paternity, or an environmentally acquired disorder.

Family planning

The optimal time for determination of genetic risk and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy. Similarly, decisions about testing to determine the genetic status of at-risk asymptomatic family members are best made before pregnancy.
It is appropriate to offer genetic counseling (including general discussion of potential risks to offspring and reproductive options) to young adults who are affected, carriers, or at risk of being affected or a carrier; however, it is not possible to make specific predictions about the potential severity of disease in offspring.

DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.

Prenatal Testing and Preimplantation Genetic Testing

Once the pathogenic variant(s) have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing for hereditary spastic paraplegia are possible.

Resources

GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click here.

EURO HSP
Plateforme Maladies Rares
99 Rue Didot
Paris 75014
France
Phone: 33 1 56 53 52 61
Email: president@eurohsp.eu
www.eurohsp.eu
HSP Research Foundation
P.O. Box 4064
Warrimoo New South Wales NSW 2774
Australia
www.hspersunite.org.au
National Institute of Neurological Disorders and Stroke (NINDS)
PO Box 5801
Bethesda MD 20824
Phone: 800-352-9424 (toll-free); 301-496-5751; 301-468-5981 (TTY)
Hereditary Spastic Paraplegia Information Page
Spastic Paraplegia Foundation, Inc.
7700 Leesburg Pike
Ste 123
Falls Church VA 22043
Phone: 877-773-4483 (toll-free)
Email: information@sp-foundation.org
sp-foundation.org
Tom Wahlig-Foundation
Tom Wahlig Stiftung
Büro Veghestrasse 22
Germany
Phone: 49 (0) 251 - 20 07 91 20
Email: nfo@hsp-info.de
www.hsp-info.de/en/foundation.htm
A.I. Vi.P.S.
Associazione Italiana Vivere la Paraparesi Spastica Onlus
Via Tevere, 7
20020 Lainate (MI)
Italy
Phone: 39 392 9825622
Email: nfo@vipsonlus.it
www.vipsonlus.it

References

Literature Cited

Abou Jamra R, Philippe O, Raas-Rothschild A, Eck SH, Graf E, Buchert R, Borck G, Ekici A, Brockschmidt FF, Nöthen MM, Munnich A, Strom TM, Reis A, Colleaux L. Adaptor protein complex 4 deficiency causes severe autosomal-recessive intellectual disability, progressive spastic paraplegia, shy character, and short stature. Am J Hum Genet. 2011;88:788–95. [PMC free article: PMC3113253] [PubMed: 21620353]
Alazami AM, Adly N, Al Dhalaan H, Alkuraya FS. A nullimorphic ERLIN2 mutation defines a complicated hereditary spastic paraplegia locus (SPG18). Neurogenetics. 2011;12:333–6. [PMC free article: PMC3215864] [PubMed: 21796390]
Al-Saif A, Bohlega S, Al-Mohanna F. Loss of ERLIN2 function leads to juvenile primary lateral sclerosis. Ann Neurol. 2012;72:510–6. [PubMed: 23109145]
Arnoldi A, Tonelli A, Crippa F, Villani G, Pacelli C, Sironi M, Pozzoli U, D'Angelo MG, Meola G, Martinuzzi A, Crimella C, Redaelli F, Panzeri C, Renieri A, Comi GP, Turconi AC, Bresolin N, Bassi MT. A clinical, genetic, and biochemical characterization of SPG7 mutations in a large cohort of patients with hereditary spastic paraplegia. Hum Mutat. 2008;29:522–31. [PubMed: 18200586]
Aulitzky A, Friedrich K, Gläser D, Gastl R, Kubisch C, Ludolph AC, Volk AE. A complex form of hereditary spastic paraplegia in three siblings due to somatic mosaicism for a novel SPAST mutation in the mother. J Neurol Sci. 2014;347:352–5. [PubMed: 25315759]
Bauer P, Leshinsky-Silver E, Blumkin L, Schlipf N, Schröder C, Schicks J, Lev D, Riess O, Lerman-Sagie T, Schöls L. Mutation in the AP4B1 gene cause hereditary spastic paraplegia type 47 (SPG47). Neurogenetics. 2012;13:73–6. [PubMed: 22290197]
Bayrakli F, Poyrazoglu HG, Yuksel S, Yakicier C, Erguner B, Sagiroglu MS, Yuceturk B, Ozer B, Doganay S, Tanrikulu B, Seker A, Akbulut F, Ozen A, Per H, Kumandas S, Altuner Torun Y, Bayri Y, Sakar M, Dagcinar A, Ziyal I. Hereditary spastic paraplegia with recessive trait caused by mutation in KLC4 gene. J Hum Genet. 2015;60:763–8. [PubMed: 26423925]
Beetz C, Johnson A, Schuh AL, Thakur S, Varga RE, Fothergill T, Hertel N, Bomba-Warczak E, Thiele H, Nürnberg G, Altmüller J, Saxena R, Chapman ER, Dent EW, Nürnberg P, Audhya A. Inhibition of TFG function causes hereditary axon degeneration by impairing endoplasmicreticulum structure. Proc Natl Acad Sci U S A. 2013;110:5091–6. [PMC free article: PMC3612678] [PubMed: 23479643]
Blair MA, Ma S, Hedera P. Mutation in KIF5A can also cause adult-onset hereditary spastic paraplegia. Neurogenetics. 2006;7:47–50. [PubMed: 16489470]
Boccone L, Mariotti S, Dessì V, Pruna D, Meloni A, Loudianos G. Allan-Herndon-Dudley syndrome (AHDS) caused by a novel SLC16A2 gene mutation showing severe neurologic features and unexpectedly low TRH-stimulated serum TSH. Eur J Med Genet. 2010;53:392–5. [PubMed: 20713192]
Boukhris A, Schule R, Loureiro JL, Lourenço CM, Mundwiller E, Gonzalez MA, Charles P, Gauthier J, Rekik I, Acosta Lebrigio RF, Gaussen M, Speziani F, Ferbert A, Feki I, Caballero-Oteyza A, Dionne-Laporte A, Amri M, Noreau A, Forlani S, Cruz VT, Mochel F, Coutinho P, Dion P, Mhiri C, Schols L, Pouget J, Darios F, Rouleau GA, Marques W Jr, Brice A, Durr A, Zuchner S, Stevanin G. Alteration of ganglioside biosynthesis responsible for complex hereditary spastic paraplegia. Am J Hum Genet. 2013;93:118–23. [PMC free article: PMC3710753] [PubMed: 23746551]
Brugman F, Scheffer H, Wokke JH, Nillesen WM, de Visser M, Aronica E, Veldink JH, van den Berg LH. Paraplegin mutations in sporadic adult-onset upper motor neuron syndromes. Neurology. 2008;71:1500–5. [PubMed: 18799786]
Caballero Oteyza A, Battaloğlu E, Ocek L, Lindig T, Reichbauer J, Rebelo AP, Gonzalez MA, Zorlu Y, Ozes B, Timmann D, Bender B, Woehlke G, Züchner S, Schöls L, Schüle R. Motor protein mutations cause a new form of hereditary spastic paraplegia. Neurology. 2014;82:2007–16. [PMC free article: PMC4105256] [PubMed: 24808017]
Cambi F, Tang XM, Cordray P, Fain PR, Keppen LD, Barker DF. Refined genetic mapping and proteolipid protein mutation analysis in X-linked pure hereditary spastic paraplegia. Neurology. 1996;46:1112–7. [PubMed: 8780101]
Casari G, De Fusco M, Ciarmatori S, Zeviani M, Mora M, Fernandez P, De Michele G, Filla A, Cocozza S, Marconi R, Dürr A, Fontaine B, Ballabio A. Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease. Cell. 1998;93:973–83. [PubMed: 9635427]
Coarelli G, Romano S, Travaglini L, Ferraldeschi M, Nicita F, Spadaro M, Fornasiero A, Frontali M, Salvetti M, Bertini E, Ristori G. Novel homozygous GBA2 mutation in a patient with complicated spastic paraplegia. Clin Neurol Neurosurg. 2018;168:60–3. [PubMed: 29524657]
Cooper HM, Yang Y, Ylikallio E, Khairullin R, Woldegebriel R, Lin KL, Euro L, Palin E, Wolf A, Trokovic R, Isohanni P, Kaakkola S, Auranen M, Lönnqvist T, Wanrooij S, Tyynismaa H. ATPase-deficient mitochondrial inner membrane protein ATAD3A disturbs mitochondrial dynamics in dominant hereditary spastic paraplegia. Hum Mol Genet. 2017;26:1432–43. [PMC free article: PMC5393146] [PubMed: 28158749]
Coutelier M, Goizet C, Durr A, Habarou F, Morais S, Dionne-Laporte A, Tao F, Konop J, Stoll M, Charles P, Jacoupy M, Matusiak R, Alonso I, Tallaksen C, Mairey M, Kennerson M, Gaussen M, Schule R, Janin M, Morice-Picard F, Durand CM, Depienne C, Calvas P, Coutinho P, Saudubray JM, Rouleau G, Brice A, Nicholson G, Darios F, Loureiro JL, Zuchner S, Ottolenghi C, Mochel F, Stevanin G. Alteration of ornithine metabolism leads to dominant and recessive hereditary spastic paraplegia. Brain. 2015;138:2191–205. [PMC free article: PMC4553756] [PubMed: 26026163]
Cross HE, McKusick VA. The mast syndrome. A recessively inherited form of presenile dementia with motor disturbances. Arch Neurol. 1967a;16:1–13. [PubMed: 6024251]
Cross HE, McKusick VA. The Troyer syndrome: a recessive form of spastic paraplegia with distal muscle wasting. Arch Neurol. 1967b;16:473–85. [PubMed: 6022528]
Crow YJ, Zaki MS, Abdel-Hamid MS, Abdel-Salam G, Boespflug-Tanguy O, Cordeiro NJ, Gleeson JG, Gowrinathan NR, Laugel V, Renaldo F, Rodriguez D, Livingston JH, Rice GI. Mutations in ADAR1, IFIH1, and RNASEH2B presenting as spastic paraplegia. Neuropediatrics. 2014;45:386–93. [PubMed: 25243380]
Dick KJ, Eckhardt M, Paisán-Ruiz C, Alshehhi AA, Proukakis C, Sibtain NA, Maier H, Sharifi R, Patton MA, Bashir W, Koul R, Raeburn S, Gieselmann V, Houlden H, Crosby AH. Mutation of FA2H underlies a complicated form of hereditary spastic paraplegia (SPG35). Hum Mutat. 2010;31:E1251–60. [PubMed: 20104589]
Dor T, Cinnamon Y, Raymond L, Shaag A, Bouslam N, Bouhouche A, Gaussen M, Meyer V, Durr A, Brice A, Benomar A, Stevanin G, Schuelke M, Edvardson S. KIF1C mutations in two families with hereditary spastic paraparesis and cerebellar dysfunction. J Med Genet. 2014;51:137–42. [PubMed: 24319291]
Du JS, Bason L, Woffendin H, Zackai E, Kenwrick S. Somatic and germ line mosaicism and mutation origin for a mutation in the L1 gene in a family with X-linked hydrocephalus. Am J Med Genet. 1998;75:200–2. [PubMed: 9450886]
Du J, Hu YC, Tang BS, Chen C, Luo YY, Zhan ZX, Zhao GH, Jiang H, Xia K, Shen L. Expansion of the phenotypic spectrum of SPG6 caused by mutation in NIPA1. Clin Neurol Neurosurg. 2011;113:480–2. [PubMed: 21419568]
Dumitrescu AM, Liao XH, Best TB, Brockmann K, Refetoff S. A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. Am J Hum Genet. 2004;74:168–75. [PMC free article: PMC1181904] [PubMed: 14661163]
Edvardson S, Hama H, Shaag A, Gomori JM, Berger I, Soffer D, Korman SH, Taustein I, Saada A, Elpeleg O. Mutations in the fatty acid 2-hydroxylase gene are associated with leukodystrophy with spastic paraparesis and dystonia. Am J Hum Genet. 2008;83:643–8. [PMC free article: PMC2668027] [PubMed: 19068277]
Elsaid MF, Ibrahim K, Chalhoub N, Elsotouhy A, El Mudehki N, Abdel Aleem A. NT5C2 novel splicing variant expands the phenotypic spectrum of spastic paraplegia (SPG45): case report of a new member of thin corpus callosum SPG-Subgroup. BMC Med Genet. 2017;18:33. [PMC free article: PMC5359868] [PubMed: 28327087]
Esteves T, Durr A, Mundwiller E, Loureiro JL, Boutry M, Gonzalez MA, Gauthier J, El-Hachimi KH, Depienne C, Muriel MP, Acosta Lebrigio RF, Gaussen M, Noreau A, Speziani F, Dionne-Laporte A, Deleuze JF, Dion P, Coutinho P, Rouleau GA, Zuchner S, Brice A, Stevanin G, Darios F. Loss of association of REEP2 with membranes leads to hereditary spastic paraplegia. Am J Hum Genet. 2014;94:268–77. [PMC free article: PMC3928657] [PubMed: 24388663]
Finckh U, Schroder J, Ressler B, Veske A, Gal A. Spectrum and detection rate of L1CAM mutations in isolated and familial cases with clinically suspected L1-disease. Am J Med Genet. 2000;92:40–6. [PubMed: 10797421]
Fonknechten N, Mavel D, Byrne P, Davoine CS, Cruaud C, Bönsch D, Samson D, Coutinho P, Hutchinson M, McMonagle P, Burgunder JM, Tartaglione A, Heinzlef O, Feki I, Deufel T, Parfrey N, Brice A, Fontaine B, Prud'homme JF, Weissenbach J, Dürr A, Hazan J. Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia. Hum Mol Genet. 2000;9:637–44. [PubMed: 10699187]
Goizet C, Boukhris A, Durr A, Beetz C, Truchetto J, Tesson C, Tsaousidou M, Forlani S, Guyant-Maréchal L, Fontaine B, Guimarães J, Isidor B, Chazouillères O, Wendum D, Grid D, Chevy F, Chinnery PF, Coutinho P, Azulay JP, Feki I, Mochel F, Wolf C, Mhiri C, Crosby A, Brice A, Stevanin G. CYP7B1 mutations in pure and complex forms of hereditary spastic paraplegia type 5. Brain. 2009;132:1589–600. [PubMed: 19439420]
Gonzalez M, McLaughlin H, Houlden H, Guo M, Yo-Tsen L, Hadjivassilious M, Speziani F, Yang XL, Antonellis A, Reilly MM, Züchner S., Inherited Neuropathy Consortium. Exome sequencing identifies a significant variant in methionyl-tRNA synthetase (MARS) in a family with late-onset CMT2. J Neurol Neurosurg Psychiatry. 2013;84:1247–9. [PMC free article: PMC3796032] [PubMed: 23729695]
Gordon N. Sjögren-Larsson syndrome. Dev Med Child Neurol. 2007;49:152–4. [PubMed: 17254005]
Guidubaldi A, Piano C, Santorelli FM, Silvestri G, Petracca M, Tessa A, Bentivoglio AR. Novel mutations in SPG11 cause hereditary spastic paraplegia associated with early-onset levodopa-responsive Parkinsonism. Mov Disord. 2011;26:553–6. [PubMed: 21381113]
Hamdan FF, Gauthier J, Araki Y, Lin DT, Yoshizawa Y, Higashi K, Park AR, Spiegelman D, Dobrzeniecka S, Piton A, Tomitori H, Daoud H, Massicotte C, Henrion E, Diallo O. S2D Group, Shekarabi M, Marineau C, Shevell M, Maranda B, Mitchell G, Nadeau A, D'Anjou G, Vanasse M, Srour M, Lafrenière RG, Drapeau P, Lacaille JC, Kim E, Lee JR, Igarashi K, Huganir RL, Rouleau GA, Michaud JL. Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability. Am J Hum Genet. 2011;88:306–16. [PMC free article: PMC3059427] [PubMed: 21376300]
Hammer MB, Eleuch-Fayache G, Schottlaender LV, Nehdi H, Gibbs JR, Arepalli SK, Chong SB, Hernandez DG, Sailer A, Liu G, Mistry PK, Cai H, Shrader G, Sassi C, Bouhlal Y, Houlden H, Hentati F, Amouri R, Singleton AB. Mutations in GBA2 cause autosomal-recessive cerebellar ataxia with spasticity. Am J Hum Genet. 2013;92:245–51. [PMC free article: PMC3567281] [PubMed: 23332917]
Hanein S, Martin E, Boukhris A, Byrne P, Goizet C, Hamri A, Benomar A, Lossos A, Denora P, Fernandez J, Elleuch N, Forlani S, Durr A, Feki I, Hutchinson M, Santorelli FM, Mhiri C, Brice A, Stevanin G. Identification of the SPG15 gene, encoding spastizin, as a frequent cause of complicated autosomal-recessive spastic paraplegia, including Kjellin syndrome. Am J Hum Genet. 2008;82:992–1002. [PMC free article: PMC2427184] [PubMed: 18394578]
Hansen JJ, Dürr A, Cournu-Rebeix I, Georgopoulos C, Ang D, Nielsen MN, Davoine CS, Brice A, Fontaine B, Gregersen N, Bross P. Hereditary spastic paraplegia SPG13 is associated with a mutation in the gene encoding the mitochondrial chaperonin Hsp60. Am J Hum Genet. 2002;70:1328–32. [PMC free article: PMC447607] [PubMed: 11898127]
Hardies K, May P, Djémié T, Tarta-Arsene O, Deconinck T, Craiu D. AR working group of the EuroEPINOMICS RES Consortium, Helbig I, Suls A, Balling R, Weckhuysen S, De Jonghe P, Hirst J. Recessive loss-of-function mutations in AP4S1 cause mild fever-sensitive seizures, developmental delay and spastic paraplegia through loss of AP-4 complex assembly. Hum Mol Genet. 2015;24:2218–27. [PMC free article: PMC4380070] [PubMed: 25552650]
Harding AE. Classification of the hereditary ataxias and paraplegias. Lancet. 1983;1:1151–5. [PubMed: 6133167]
Harlalka GV, Lehman A, Chioza B, Baple EL, Maroofian R, Cross H, Sreekantan-Nair A, Priestman DA, Al-Turki S, McEntagart ME, Proukakis C, Royle L, Kozak RP, Bastaki L, Patton M, Wagner K, Coblentz R, Price J, Mezei M, Schlade-Bartusiak K, Platt FM, Hurles ME, Crosby AH. Mutations in B4GALNT1 (GM2 synthase) underlie a new disorder of ganglioside biosynthesis. Brain. 2013;136:3618–24. [PMC free article: PMC3859217] [PubMed: 24103911]
Hazan J, Fonknechten N, Mavel D, Paternotte C, Samson D, Artiguenave F, Davoine CS, Cruaud C, Dürr A, Wincker P, Brottier P, Cattolico L, Barbe V, Burgunder JM, Prud'homme JF, Brice A, Fontaine B, Heilig B, Weissenbach J. Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat Genet. 1999;23:296–303. [PubMed: 10610178]
Hedera P. Hereditary and metabolic myelopathies. Handb Clin Neurol. 2016;136:769–85. [PubMed: 27430441]
Hedera P. Recurrent de novo c.316G>A mutation in NIPA1 hotspot. J Neurol Sci. 2013;335:231–2. [PubMed: 24075313]
Hedera P, DiMauro S, Bonilla E, Wald J, Eldevik OP, Fink JK. Phenotypic analysis of autosomal dominant hereditary spastic paraplegia linked to chromosome 8q. Neurology. 1999;53:44–50. [PubMed: 10408535]
Hewamadduma C, McDermott C, Kirby J, Grierson A, Panayi M, Dalton A, Rajabally Y, Shaw P. New pedigrees and novel mutation expand the phenotype of REEP1-associated hereditary spastic paraplegia (HSP). Neurogenetics. 2009;10:105–10. [PubMed: 19034539]
Hodes ME, Zimmerman AW, Aydanian A, Naidu S, Miller NR, Garcia Oller JL, Barker B, Aleck KA, Hurley TD, Dlouhy SR. Different mutations in the same codon of the proteolipid protein gene, PLP, may help in correlating genotype with phenotype in Pelizaeus-Merzbacher disease/X-linked spastic paraplegia (PMD/SPG2). Am J Med Genet. 1999;82:132–9. [PubMed: 9934976]
Hufnagel RB, Arno G, Hein ND, Hersheson J, Prasad M, Anderson Y, Krueger LA, Gregory LC, Stoetzel C, Jaworek TJ, Hull S, Li A, Plagnol V, Willen CM, Morgan TM, Prows CA, Hegde RS, Riazuddin S, Grabowski GA, Richardson RJ, Dieterich K, Huang T, Revesz T, Martinez-Barbera JP, Sisk RA, Jefferies C, Houlden H, Dattani MT, Fink JK, Dollfus H, Moore AT, Ahmed ZM. Neuropathy target esterase impairments cause Oliver-McFarlane and Laurence-Moon syndromes. J Med Genet. 2015;52:85–94. [PubMed: 25480986]
Ishiura H, Takahashi Y, Hayashi T, Saito K, Furuya H, Watanabe M, Murata M, Suzuki M, Sugiura A, Sawai S, Shibuya K, Ueda N, Ichikawa Y, Kanazawa I, Goto J, Tsuji S. Molecular epidemiology and clinical spectrum of hereditary spastic paraplegia in the Japanese population based on comprehensive mutational analyses. J Hum Genet. 2014;59:163–72. [PubMed: 24451228]
Ivanova N, Claeys KG, Deconinck T, Litvinenko I, Jordanova A, Auer-Grumbach M, Haberlova J, Löfgren A, Smeyers G, Nelis E, Mercelis R, Plecko B, Priller J, Zámecník J, Ceulemans B, Erichsen AK, Björck E, Nicholson G, Sereda MW, Seeman P, Kremensky I, Mitev V, De Jonghe P. Hereditary spastic paraplegia 3A associated with axonal neuropathy. Arch Neurol. 2007;64:706–13. [PubMed: 17502470]
Jouet M, Rosenthal A, Armstrong G, MacFarlane J, Stevenson R, Paterson J, Metzenberg A, Ionasescu V, Temple K, Kenwrick S. X-linked spastic paraplegia (SPG1), MASA syndrome and X-linked hydrocephalus result from mutations in the L1 gene. Nat Genet. 1994;7:402–7. [PubMed: 7920659]
Kancheva D, Chamova T, Guergueltcheva V, Mitev V, Azmanov DN, Kalaydjieva L, Tournev I, Jordanova A. Mosaic dominant TUBB4A mutation in an inbred family with complicated hereditary spastic paraplegia. Mov Disord. 2015;30:854–8. [PubMed: 25772097]
Khan TN, Klar J, Tariq M, Anjum Baig S, Malik NA, Yousaf R, Baig SM, Dahl N. Evidence for autosomal recessive inheritance in SPG3A caused by homozygosity for a novel ATL1 missense mutation. Eur J Hum Genet. 2014;22:1180–4. [PMC free article: PMC4169543] [PubMed: 24473461]
Klebe S, Lossos A, Azzedine H, Mundwiller E, Sheffer R, Gaussen M, Marelli C, Nawara M, Carpentier W, Meyer V, Rastetter A, Martin E, Bouteiller D, Orlando L, Gyapay G, El-Hachimi KH, Zimmerman B, Gamliel M, Misk A, Lerer I, Brice A, Durr A, Stevanin G. KIF1A missense mutations in SPG30, an autosomal recessive spastic paraplegia: distinct phenotypes according to the nature of the mutations. Eur J Hum Genet. 2012;20:645–9. [PMC free article: PMC3355258] [PubMed: 22258533]
Kortüm F, Jamra RA, Alawi M, Berry SA, Borck G, Helbig KL, Tang S, Huhle D, Korenke GC, Hebbar M, Shukla A, Girisha KM, Steinlin M, Waldmeier-Wilhelm S, Montomoli M, Guerrini R, Lemke JR, Kutsche K. Clinical and genetic spectrum of AMPD2-related pontocerebellar hypoplasia type 9. Eur J Hum Genet. 2018;26:695–708. [PMC free article: PMC5945775] [PubMed: 29463858]
Landouré G, Zhu PP, Lourenço CM, Johnson JO, Toro C, Bricceno KV, Rinaldi C, Meilleur KG, Sangaré M, Diallo O, Pierson TM, Ishiura H, Tsuji S, Hein N, Fink JK, Stoll M, Nicholson G, Gonzalez MA, Speziani F, Dürr A, Stevanin G, Biesecker LG. NIH Intramural Sequencing Center, Accardi J, Landis DM, Gahl WA, Traynor BJ, Marques W Jr, Züchner S, Blackstone C, Fischbeck KH, Burnett BG. Hereditary spastic paraplegia type 43 (SPG43) is caused by mutation in C19orf12. Hum Mutat. 2013;34:1357–60. [PMC free article: PMC3819934] [PubMed: 23857908]
Li M, Ho PW, Pang SY, Tse ZH, Kung MH, Sham PC, Ho SL. PMCA4 (ATP2B4) mutation in familial spastic paraplegia. PLoS One. 2014;9:e104790. [PMC free article: PMC4132067] [PubMed: 25119969]
Lin P, Li J, Liu Q, Mao F, Li J, Qiu R, Hu H, Song Y, Yang Y, Gao G, Yan C, Yang W, Shao C, Gong Y. A missense mutation in SLC33A1, which encodes the acetyl-CoA transporter, causes autosomal-dominant spastic paraplegia (SPG42). Am J Hum Genet. 2008;83:752–9. [PMC free article: PMC2668077] [PubMed: 19061983]
Liu YT, Laurá M, Hersheson J, Horga A, Jaunmuktane Z, Brandner S, Pittman A, Hughes D, Polke JM, Sweeney MG, Proukakis C, Janssen JC, Auer-Grumbach M, Zuchner S, Shields KG, Reilly MM, Houlden H. Extended phenotypic spectrum of KIF5A mutations: from spastic paraplegia to axonal neuropathy. Neurology. 2014;83:612–9. [PMC free article: PMC4141994] [PubMed: 25008398]
Lossos A, Stümpfig C, Stevanin G, Gaussen M, Zimmerman BE, Mundwiller E, Asulin M, Chamma L, Sheffer R, Misk A, Dotan S, Gomori JM, Ponger P, Brice A, Lerer I, Meiner V, Lill R. Fe/S protein assembly gene IBA57 mutation causes hereditary spastic paraplegia. Neurology. 2015;84:659–67. [PubMed: 25609768]
Lynex CN, Carr IM, Leek JP, Achuthan R, Mitchell S, Maher ER, Woods CG, Bonthon DT, Markham AF. Homozygosity for a missense mutation in the 67 kDa isoform of glutamate decarboxylase in a family with autosomal recessive spastic cerebral palsy: parallels with stiff-person syndrome and other movement disorders. BMC Neurol. 2004;4:20. [PMC free article: PMC544830] [PubMed: 15571623]
Maier A, Klopocki E, Horn D, Tzschach A, Holm T, Meyer R, Meyer T. De novo partial deletion in GRID2 presenting with complicated spastic paraplegia. Muscle Nerve. 2014;49:289–92. [PubMed: 24122788]
Mannan AU, Krawen P, Sauter SM, Boehm J, Chronowska A, Paulus W, Neesen J, Engel W. ZFYVE27 (SPG33), a novel spastin-binding protein, is mutated in hereditary spastic paraplegia. Am J Hum Genet. 2006;79:351–7. [PMC free article: PMC1559503] [PubMed: 16826525]
McDermott CJ, Dayaratne RK, Tomkins J, Lusher ME, Lindsey JC, Johnson MA, Casari G, Turnbull DM, Bushby K, Shaw PJ. Paraplegin gene analysis in hereditary spastic paraparesis (HSP) pedigrees in northeast England. Neurology. 2001;56:467–71. [PubMed: 11222789]
Melo US, Macedo-Souza LI, Figueiredo T, Muotri AR, Gleeson JG, Coux G, Armas P, Calcaterra NB, Kitajima JP, Amorim S, Olávio TR, Griesi-Oliveira K, Coatti GC, Rocha CR, Martins-Pinheiro M, Menck CF, Zaki MS, Kok F, Zatz M, Santos S. Overexpression of KLC2 due to a homozygous deletion in the non-coding region causes SPOAN syndrome. Hum Mol Genet. 2015;24:6877–85. [PMC free article: PMC6296331] [PubMed: 26385635]
Montenegro G, Rebelo AP, Connell J, Allison R, Babalini C, D'Aloia M, Montieri P, Schüle R, Ishiura H, Price J, Strickland A, Gonzalez MA, Baumbach-Reardon L, Deconinck T, Huang J, Bernardi G, Vance JM, Rogers MT, Tsuji S, De Jonghe P, Pericak-Vance MA, Schöls L, Orlacchio A, Reid E, Züchner S. Mutations in the ER-shaping protein reticulon 2 cause the axon-degenerative disorder hereditary spastic paraplegia type 12. J Clin Invest. 2012;122:538–44. [PMC free article: PMC3266795] [PubMed: 22232211]
Moreno-De-Luca A, Helmers SL, Mao H, Burns TG, Melton AM, Schmidt KR, Fernhoff PM, Ledbetter DH, Martin CL. J Med Genet. 2011;48:141–4. [PMC free article: PMC3150730] [PubMed: 20972249]
Murakami Y, Tawamie H, Maeda Y, Büttner C, Buchert R, Radwan F, Schaffer S, Sticht H, Aigner M, Reis A, Kinoshita T, Jamra RA. Null mutation in PGAP1 impairing Gpi-anchor maturation in patients with intellectual disability and encephalopathy. PLoS Genet. 2014;10:e1004320. [PMC free article: PMC4006728] [PubMed: 24784135]
Murphy S, Gorman G, Beetz C, Byrne P, Dytko M, McMonagle P, Kinsella K, Farrell M, Hutchinson M. Dementia in SPG4 hereditary spastic paraplegia: clinical, genetic, and neuropathologic evidence. Neurology. 2009;73:378–84. [PubMed: 19652142]
Musacchio T, Zaum AK, Üçeyler N, Sommer C, Pfeifroth N, Reiners K, Kunstmann E, Volkmann J, Rost S, Klebe S. ALS and MMN mimics in patients with BSCL2 mutations: the expanding clinical spectrum of SPG17 hereditary spastic paraplegia. J Neurol. 2017;264:11–20. [PubMed: 27738760]
Namekawa M, Ribai P, Nelson I, Forlani S, Fellmann F, Goizet C, Depienne C, Stevanin G, Ruberg M, Dürr A, Brice A. SPG3A is the most frequent cause of hereditary spastic paraplegia with onset before age 10 years. Neurology. 2006;66:112–14. [PubMed: 16401858]
Nielsen JE, Johnsen B, Koefoed P, Scheuer KH, Grønbech-Jensen M, Law I, Krabbe K, Nørremølle A, Eiberg H, Søndergård H, Dam M, Rehfeld JF, Krarup C, Paulson OB, Hasholt L, Sørensen SA. Hereditary spastic paraplegia with cerebellar ataxia: a complex phenotype associated with a new SPG4 gene mutation. Eur J Neurol. 2004;11:817–24. [PubMed: 15667412]
Novarino G, Fenstermaker AG, Zaki MS, Hofree M, Silhavy JL, Heiberg AD, Abdellateef M, Rosti B, Scott E, Mansour L, Masri A, Kayserili H, Al-Aama JY, Abdel-Salam GMH, Karminejad A, Kara M, Kara B, Bozorgmehri B, Ben-Omran T, Mojahedi F, El Din Mahmoud IG, Bouslam N, Bouhouche A, Benomar A, Hanein S, Raymond L, Forlani S, Mascaro M, Selim L, Shehata N, Al-Allawi N, Bindu PS, Azam M, Gunel M, Caglayan A, Bilguvar K, Tolun A, Issa MY, Schroth J, Spencer EG, Rosti RO, Akizu N, Vaux KK, Johansen A, Koh AA, Megahed H, Durr A, Brice A, Stevanin G, Gabriel SB, Ideker T, Gleeson JG. Exome sequencing links corticospinal motor neuron disease to common neurodegenerative disorders. Science. 2014;343:506–11. [PMC free article: PMC4157572] [PubMed: 24482476]
Oates EC, Rossor AM, Hafezparast M, Gonzalez M, Speziani F, MacArthur DG, Lek M, Cottenie E, Scoto M, Foley AR, Hurles M, Houlden H, Greensmith L, Auer-Grumbach M, Pieber TR, Strom TM, Schule R, Herrmann DN, Sowden JE, Acsadi G, Menezes MP, Clarke NF, Züchner S. UK10K, Muntoni F, North KN, Reilly MM. Mutations in BICD2 cause dominant congenital spinal muscular atrophy and hereditary spastic paraplegia. Am J Hum Genet. 2013;92:965–73. [PMC free article: PMC3675232] [PubMed: 23664120]
Orthmann-Murphy JL, Salsano E, Abrams CK, Bizzi A, Uziel G, Freidin MM, Lamantea E, Zeviani M, Scherer SS, Pareyson D. Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations. Brain. 2009;132:426–38. [PMC free article: PMC2640216] [PubMed: 19056803]
Oz-Levi D, Ben-Zeev B, Ruzzo EK, Hitomi Y, Gelman A, Pelak K, Anikster Y, Reznik-Wolf H, Bar-Joseph I, Olender T, Alkelai A, Weiss M, Ben-Asher E, Ge D, Shianna KV, Elazar Z, Goldstein DB, Pras E, Lancet D. Mutation in TECPR2 reveals a role for autophagy in hereditary spastic paraparesis. Am J Hum Genet. 2012;91:1065–72. [PMC free article: PMC3516605] [PubMed: 23176824]
Paisan-Ruiz C, Dogu O, Yilmaz A, Houlden H, Singleton A. SPG11 mutations are common in familial cases of complicated hereditary spastic paraplegia. Neurology. 2008;70:1384–9. [PMC free article: PMC2730021] [PubMed: 18337587]
Patel H, Cross H, Proukakis C, Hershberger R, Bork P, Ciccarelli FD, Patton MA, McKusick VA, Crosby AH. SPG20 is mutated in Troyer syndrome, an hereditary spastic paraplegia. Nat Genet. 2002;31:347–8. [PubMed: 12134148]
Pensato V, Castellotti B, Gellera C, Pareyson D, Ciano C, Nanetti L, Salsano E, Piscosquito G, Sarto E, Eoli M, Moroni I, Soliveri P, Lamperti E, Chiapparini L, Di Bella D, Taroni F, Mariotti C. Overlapping phenotypes in complex spastic paraplegias SPG11, SPG15, SPG35 and SPG48. Brain. 2014;137:1907–20. [PubMed: 24833714]
Rainier S, Bui M, Mark E, Thomas D, Tokarz D, Ming L, Delaney C, Richardson RJ, Albers JW, Matsunami N, Stevens J, Coon H, Leppert M, Fink JK. Neuropathy target esterase gene mutations cause motor neuron disease. Am J Hum Genet. 2008;82:780–5. [PMC free article: PMC2427280] [PubMed: 18313024]
Rainier S, Chai JH, Tokarz D, Nicholls RD, Fink JK. NIPA1 gene mutations cause autosomal dominant hereditary spastic paraplegia (SPG6). Am J Hum Genet. 2003;73:967–71. [PMC free article: PMC1180617] [PubMed: 14508710]
Rainier S, Sher C, Reish O, Thomas D, Fink JK. De novo occurrence of novel SPG3A/atlastin mutation presenting as cerebral palsy. Arch Neurol. 2006;63:445–7. [PubMed: 16533974]
Reid E, Kloos M, Ashley-Koch A, Hughes L, Bevan S, Svenson IK, Graham FL, Gaskell PC, Dearlove A, Pericak-Vance MA, Rubinsztein DC, Marchuk DA. A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am J Hum Genet. 2002;71:1189–94. [PMC free article: PMC385095] [PubMed: 12355402]
Rinaldi C, Schmidt T, Situ AJ, Johnson JO, Lee PR, Chen KL, Bott LC, Fadó R, Harmison GH, Parodi S, Grunseich C, Renvoisé B, Biesecker LG, De Michele G, Santorelli FM, Filla A, Stevanin G, Dürr A, Brice A, Casals N, Traynor BJ, Blackstone C, Ulmer TS, Fischbeck KH. Mutation in CPT1C associated with pure autosomal dominant spastic paraplegia. JAMA Neurol. 2015;72:561–70. [PMC free article: PMC5612424] [PubMed: 25751282]
Riverol M, Samaranch L, Pascual B, Pastor P, Irigoyen J, Pastor MA, de Castro P, Masdeu JC. Forceps minor region signal abnormality "ears of the lynx": an early MRI finding in spastic paraparesis with thin corpus callosum and mutations in the spatascin gene (SPG11) on chromosome 15. J Neuroimaging. 2009;19:52–60. [PubMed: 19040626]
Rivière JB, Ramalingam S, Lavastre V, Shekarabi M, Holbert S, Lafontaine J, Srour M, Merner N, Rochefort D, Hince P, Gaudet R, Mes-Masson AM, Baets J, Houlden H, Brais B, Nicholson GA, Van Esch H, Nafissi S, De Jonghe P, Reilly MM, Timmerman V, Dion PA, Rouleau GA. KIF1A, an axonal transporter of synaptic vesicles, is mutated in hereditary sensory and autonomic neuropathy type 2. Am J Hum Genet. 2011;89:219–30. [PMC free article: PMC3155159] [PubMed: 21820098]
Rizzo WB, Carney G, Lin Z. The molecular basis of Sjögren-Larsson syndrome: mutation analysis of the fatty aldehyde dehydrogenase gene. Am J Hum Genet. 1999;65:1547–60. [PMC free article: PMC1288365] [PubMed: 10577908]
Rydning SL, Dudesek A, Rimmele F, Funke C, Krüger S, Biskup S, Vigeland MD, Hjorthaug HS, Sejersted Y, Tallaksen C, Selmer KK, Kamm C. A novel heterozygous variant in ERLIN2 causes autosomal dominant pure hereditary spastic paraplegia. Eur J Neurol. 2018;25:943–e71. [PubMed: 29528531]
Sambuughin N, Goldfarb LG, Sivtseva TM, Davydova TK, Vladimirtsev VA, Osakovskiy VL, Danilova AP, Nikitina RS, Ylakhova AN, Diachkovskaya MP, Sundborger AC, Renwick NM, Platonov FA, Hinshaw JE, Toro C. Adult-onset autosomal dominant spastic paraplegia linked to a GTPase-effector domain mutation of dynamin 2. BMC Neurol. 2015;15:223. [PMC free article: PMC4628244] [PubMed: 26517984]
Saugier-Veber P, Munnich A, Bonneau D, Rozet JM, Le Merrer M, Gil R, Boespflug-Tanguy O. X-linked spastic paraplegia and Pelizaeus-Merzbacher disease are allelic disorders at the proteolipid protein locus. Nat Genet. 1994;6:257–62. [PubMed: 8012387]
Schrander-Stumpel C, Höweler C, Jones M, Sommer A, Stevens C, Tinschert S, Israel J, Fryns JP. Spectrum of X-linked hydrocephalus (HSAS), MASA syndrome, and complicated spastic paraplegia (SPG1): clinical review with six additional families. Am J Med Genet. 1995;57:107–16. [PubMed: 7645588]
Schubert SF, Hoffjan S, Dekomien G. Mutational analysis of the CYP7B1, PNPLA6 and C19orf12 genes in autosomal recessive hereditary spastic paraplegia. Mol Cell Probes. 2016;30:53–5. [PubMed: 26714052]
Schuurs-Hoeijmakers JH, Geraghty MT, Kamsteeg EJ, Ben-Salem S, de Bot ST, Nijhof B, van de Vondervoort II, van der Graaf M, Nobau AC, Otte-Höller I, Vermeer S, Smith AC, Humphreys P, Schwartzentruber J., FORGE Canada Consortium. Ali BR, Al-Yahyaee SA, Tariq S, Pramathan T, Bayoumi R, Kremer HP, van de Warrenburg BP, van den Akker WM, Gilissen C, Veltman JA, Janssen IM, Vulto-van Silfhout AT, van der Velde-Visser S, Lefeber DJ, Diekstra A, Erasmus CE, Willemsen MA, Vissers LE, Lammens M, van Bokhoven H, Brunner HG, Wevers RA, Schenck A, Al-Gazali L, de Vries BB, de Brouwer AP. Mutations in DDHD2, encoding an intracellular phospholipase A(1), cause a recessive form of complex hereditary spastic paraplegia. Am J Hum Genet. 2012;91:1073–81. [PMC free article: PMC3516595] [PubMed: 23176823]
Schwartz CE, May MM, Carpenter NJ, Rogers RC, Martin J, Bialer MG, Ward J, Sanabria J, Marsa S, Lewis JA, Echeverri R, Lubs HA, Voeller K, Simensen RJ, Stevenson RE. Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene. Am J Hum Genet. 2005;77:41–53. [PMC free article: PMC1226193] [PubMed: 15889350]
Shimazaki H, Takiyama Y, Ishiura H, Sakai C, Matsushima Y, Hatakeyama H, Honda J, Sakoe K, Naoi T, Namekawa M, Fukuda Y, Takahashi Y, Goto J, Tsuji S, Goto Y, Nakano I., Japan Spastic Paraplegia Research Consortium (JASPAC). A homozygous mutation of C12orf65 causes spastic paraplegia with optic atrophy and neuropathy (SPG55). J Med Genet. 2012;49:777–84. [PubMed: 23188110]
Simpson MA, Cross H, Proukakis C, Pryde A, Hershberger R, Chatonnet A, Patton MA, Crosby AH. Maspardin is mutated in mast syndrome, a complicated form of hereditary spastic paraplegia associated with dementia. Am J Hum Genet. 2003;73:1147–56. [PMC free article: PMC1180493] [PubMed: 14564668]
Sivakumar K, Sambuughin N, Selenge B, Nagle JW, Baasanjav D, Hudson LD, Goldfarb LG. Novel exon 3B proteolipid protein gene mutation causing late-onset spastic paraplegia type 2 with variable penetrance in female family members. Ann Neurol. 1999;45:680–3. [PubMed: 10319897]
Słabicki M, Theis M, Krastev DB, Samsonov S, Mundwiller E, Junqueira M, Paszkowski-Rogacz M, Teyra J, Heninger AK, Poser I, Prieur F, Truchetto J, Confavreux C, Marelli C, Durr A, Camdessanche JP, Brice A, Shevchenko A, Pisabarro MT, Stevanin G, Buchholz F. A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia. PLoS Biol. 2010;8:e1000408. [PMC free article: PMC2893954] [PubMed: 20613862]
Stevanin G, Santorelli FM, Azzedine H, Coutinho P, Chomilier J, Denora PS, Martin E, Ouvrard-Hernandez AM, Tessa A, Bouslam N, Lossos A, Charles P, Loureiro JL, Elleuch N, Confavreux C, Cruz VT, Ruberg M, Leguern E, Grid D, Tazir M, Fontaine B, Filla A, Bertini E, Durr A, Brice A. Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. Nat Genet. 2007;39:366–72. [PubMed: 17322883]
Svenstrup K, Møller RS, Christensen J, Budtz-Jørgensen E, Gilling M, Nielsen JE. NIPA1 mutation in complex hereditary spastic paraplegia with epilepsy. Eur J Neurol. 2011;18:1197–9. [PubMed: 21599812]
Synofzik M, Gonzalez MA, Lourenco CM, Coutelier M, Haack TB, Rebelo A, Hannequin D, Strom TM, Prokisch H, Kernstock C, Durr A, Schols L, Lima-Martinez MM, Farooq A, Schule R, Stevanin G, Marques W Jr, Zuchner S. PNPLA6 mutations cause Boucher-Neuhauser and Gordon Holmes syndromes as part of a broad neurodegenerative spectrum. Brain. 2014;137:69–77. [PMC free article: PMC3891450] [PubMed: 24355708]
Tesson C, Nawara M, Salih MA, Rossignol R, Zaki MS, Al Balwi M, Schule R, Mignot C, Obre E, Bouhouche A, Santorelli FM, Durand CM, Oteyza AC, El-Hachimi KH, Al Drees A, Bouslam N, Lamari F, Elmalik SA, Kabiraj MM, Seidahmed MZ, Esteves T, Gaussen M, Monin ML, Gyapay G, Lechner D, Gonzalez M, Depienne C, Mochel F, Lavie J, Schols L, Lacombe D, Yahyaoui M, Al Abdulkareem I, Zuchner S, Yamashita A, Benomar A, Goizet C, Durr A, Gleeson JG, Darios F, Brice A, Stevanin G. Alteration of fatty-acid-metabolizing enzymes affects mitochondrial form and function in hereditary spastic paraplegia. Am J Hum Genet. 2012;91:1051–64. [PMC free article: PMC3516610] [PubMed: 23176821]
Torraco A, Ardissone A, Invernizzi F, Rizza T, Fiermonte G, Niceta M, Zanetti N, Martinelli D, Vozza A, Verrigni D, Di Nottia M, Lamantea E, Diodato D, Tartaglia M, Dionisi-Vici C, Moroni I, Farina L, Bertini E, Ghezzi D, Carrozzo R. Novel mutations in IBA57 are associated with leukodystrophy and variable clinical phenotypes. J Neurol. 2017;264:102–11. [PubMed: 27785568]
Tsaousidou MK, Ouahchi K, Warner TT, Yang Y, Simpson MA, Laing NG, Wilkinson PA, Madrid RE, Patel H, Hentati F, Patton MA, Hentati A, Lamont PJ, Siddique T, Crosby AH. Sequence alterations within CYP7B1 implicate defective cholesterol homeostasis in motor-neuron degeneration. Am J Hum Genet. 2008;82:510–5. [PMC free article: PMC2426914] [PubMed: 18252231]
Tunca C, Akçimen F, Coşkun C, Gündoğdu-Eken A, Kocoglu C, Çevik B, Bekircan-Kurt CE, Tan E, Başak AN. ERLIN1 mutations cause teenage-onset slowly progressive ALS in a large Turkish pedigree. Eur J Hum Genet. 2018;26:745–8. [PMC free article: PMC5945623] [PubMed: 29453415]
Uhlenberg B, Schuelke M, Rüschendorf F, Ruf N, Kaindl AM, Henneke M, Thiele H, Stoltenburg-Didinger G, Aksu F, Topaloğlu H, Nürnberg P, Hübner C, Weschke B, Gärtner J. Mutations in the gene encoding gap junction protein alpha 12 (connexin 46.6) cause Pelizaeus-Merzbacher-like disease. Am J Hum Genet. 2004;75:251–60. [PMC free article: PMC1216059] [PubMed: 15192806]
Utine GE, Haliloğlu G, Salanci B, Çetinkaya A, Kiper PÖ, Alanay Y, Aktas D, Boduroğlu K, Alikaşifoğlu M. A homozygous deletion in GRID2 causes a human phenotype with cerebellar ataxia and atrophy. J Child Neurol. 2013;28:926–32. [PubMed: 23611888]
Valdmanis PN, Meijer IA, Reynolds A, Lei A, MacLeod P, Schlesinger D, Zatz M, Reid E, Dion PA, Drapeau P, Rouleau GA. Mutations in the KIAA0196 gene at the SPG8 locus cause hereditary spastic paraplegia. Am J Hum Genet. 2007;80:152–61. [PMC free article: PMC1785307] [PubMed: 17160902]
Verkerk AJ, Schot R, Dumee B, Schellekens K, Swagemakers S, Bertoli-Avella AM, Lequin MH, Dudink J, Govaert P, van Zwol AL, Hirst J, Wessels MW, Catsman-Berrevoets C, Verheijen FW, de Graaff E, de Coo IF, Kros JM, Willemsen R, Willems PJ, van der Spek PJ, Mancini GM. Mutation in the AP4M1 gene provides a model for neuroaxonal injury in cerebral palsy. Am J Hum Genet. 2009;85:40–52. [PMC free article: PMC2706965] [PubMed: 19559397]
Verny C, Guegen N, Desquiret V, Chevrollier A, Prundean A, Dubas F, Cassereau J, Ferre M, Amati-Bonneau P, Bonneau D, Reynier P, Procaccio V. Hereditary spastic paraplegia-like disorder due to a mitochondrial ATP6 gene point mutation. Mitochondrion. 2011;11:70–5. [PubMed: 20656066]
Vits L, Chitayat D, Van Camp G, Holden JJ, Fransen E, Willems PJ. Evidence for somatic and germline mosaicism in CRASH syndrome. Hum Mutat. 1998 Suppl 1:S284–7. [PubMed: 9452110]
Windpassinger C, Auer-Grumbach M, Irobi J, Patel H, Petek E, Hörl G, Malli R, Reed JA, Dierick I, Verpoorten N, Warner TT, Proukakis C, Van den Bergh P, Verellen C, Van Maldergem L, Merlini L, De Jonghe P, Timmerman V, Crosby AH, Wagner K. Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome. Nat Genet. 2004;36:271–6. [PubMed: 14981520]
Yamasaki M, Arita N, Hiraga S, Izumoto S, Morimoto K, Nakatani S, Fujitani K, Sato N, Hayakawa T. A clinical and neuroradiological study of X-linked hydrocephalus in Japan. J Neurosurg. 1995;83:50–5. [PubMed: 7782849]
Yıldırım Y, Orhan EK, Iseri SA, Serdaroglu-Oflazer P, Kara B, Solakoğlu S, Tolun A. A frameshift mutation of ERLIN2 in recessive intellectual disability, motor dysfunction and multiple joint contractures. Hum Mol Genet. 2011;20:1886–92. [PubMed: 21330303]
Zhao X, Alvarado D, Rainier S, Lemons R, Hedera P, Weber CH, Tukel T, Apak M, Heiman-Patterson T, Ming L, Bui M, Fink JK. Mutations in a newly identified GTPase gene cause autosomal dominant hereditary spastic paraplegia. Nat Genet. 2001;29:326–31. [PubMed: 11685207]
Züchner S, Wang G, Tran-Viet KN, Nance MA, Gaskell PC, Vance JM, Ashley-Koch AE, Pericak-Vance MA. Mutations in the novel mitochondrial protein REEP1 cause hereditary spastic paraplegia type 31. Am J Hum Genet. 2006;79:365–9. [PMC free article: PMC1559498] [PubMed: 16826527]

Chapter Notes

Author History

John K Fink, MD; University of Michigan (2000-2018)
Peter Hedera (2018-present)

Revision History

27 September 2018 (ha) Comprehensive update posted live
6 February 2014 (me) Comprehensive update posted live
3 February 2009 (cd) Revision: sequence analysis for SPG5A available clinically
21 May 2008 (cd) Revision: mutations in ZFYVE26 identified as causative of SPG15
4 March 2008 (cd) Revision: sequence analysis of entire coding region available for SPG8 and SPG33
4 October 2007 (cd) Revision: sequence analysis for SPG10 available on a clinical basis
11 July 2007 (me) Comprehensive update posted live
21 October 2004 (cd) Revision: arginase deficiency added
26 February 2004 (cd) Revision: testing for SPG6 clinically available
15 October 2003 (cd) Revision: test availability
22 September 2003 (me) Comprehensive update posted live
15 August 2000 (me) Overview posted live
21 March 2000 (jf) Original submission

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (http://www.genereviews.org/) and copyright (© 1993-2021 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the GeneReviews® Copyright Notice and Usage Disclaimer. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the GeneReviews® Copyright Notice and Usage Disclaimer.

For questions regarding permissions or whether a specified use is allowed, contact: ude.wu@tssamda.

Bookshelf ID: NBK1509PMID: 20301682

GeneReviews by Title

< Prev Next >

PubReader
Print View
Cite this Page
Hedera P. Hereditary Spastic Paraplegia Overview. 2000 Aug 15 [Updated 2018 Sep 27]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021.
PDF version of this page (641K)
Disable Glossary Links

In this GeneReview

Summary
Clinical Characteristics and Recommended Treatment: Hereditary Spastic Paraplegia
Causes of Hereditary Spastic Paraplegia
Differential Diagnosis of Hereditary Spastic Paraplegia
Evaluation Strategies to Identify the Genetic Cause of Hereditary Spastic Paraplegia in a Proband
Genetic Counseling
Resources
References
Chapter Notes

GeneReviews Links

Related information

PMC
PubMed Central citations
PubMed
Links to PubMed

Recent Activity

Clear Turn Off Turn On

Hereditary Spastic Paraplegia Overview - GeneReviews®
Hereditary Spastic Paraplegia Overview - GeneReviews®

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Bookshelf

GeneReviews^® [Internet].

Hereditary Spastic Paraplegia Overview

Summary

Goal 1.

Goal 2.

Goal 3.

Goal 4.

Goal 5.

1. Clinical Characteristics and Recommended Treatment: Hereditary Spastic Paraplegia

Treatment of Manifestations

2. Causes of Hereditary Spastic Paraplegia

Table 1.

Table 2.

Table 3.

Table 4.

3. Differential Diagnosis of Hereditary Spastic Paraplegia

4. Evaluation Strategies to Identify the Genetic Cause of Hereditary Spastic Paraplegia in a Proband

5. Genetic Counseling

Mode of Inheritance

Risk to Family Members

Autosomal Dominant HSP

Autosomal Recessive HSP

X-Linked HSP

Maternal (Mitochondrial) Inheritance

Related Genetic Counseling Issues

Prenatal Testing and Preimplantation Genetic Testing

Resources

References

Literature Cited

Chapter Notes

Author History

Revision History

Views

In this GeneReview

GeneReviews Links

Related information

Similar articles in PubMed

Recent Activity